Showing 2461-2470 of 5693 results for "".
- FDA Accepts Application for Genentech’s Port Delivery System with Ranibizumab (PDS) for Treatment of Wet AMDhttps://modernod.com/news/fda-accepts-application-for-genentechs-port-delivery-system-with-ranibizumab-pds-for-treatment-of-wet-amd/2479322/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). If approved, PDS would be a first-of-its-kind therapeutic approa
- Gyroscope Announces Research Collaboration with CMRI to Develop Gene Therapy Capsidshttps://modernod.com/news/gyroscope-announces-research-collaboration-with-cmri-to-develop-gene-therapy-capsids/2479315/Gyroscope Therapeutics announced the company has entered a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver gene therapies. A team of researchers from CMRI
- Lenz Therapeutics Debuts with $47 Million Series A Financinghttps://modernod.com/news/lenz-therapeutics-debuts-with-47-million-series-a-financing/2479301/Lenz Therapeutics debuted today with a $47 million Series A financing to move the company’s lead asset, an eyedrop formulation of aceclidine, toward an NDA submission for the treatment of presbyopia. The financing was
- J&J Vision Launches Tecnis Eyhance Toric II IOL with Tecnis Simplicity Delivery System in Europehttps://modernod.com/news/jj-vision-announces-launch-of-tecnis-eyhance-toric-ii-iol-with-tecnis-simplicity-delivery-system-in-europe/2479274/Johnson & Johnson Vision announced the launch and availability of its Tecnis Eyhance Toric II IOL with Tecnis Simplicity Delivery System for the treatment of cataracts patients with astigmatism in Europe. This monofocal lens allows for high-quality vision at both intermediate and far distance
- Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of Eyetelligence Clinical Decision Support Softwarehttps://modernod.com/news/bausch-lomb-and-lochan-enter-into-agreement-to-develop-the-next-generation-of-eyetelligence-clinical-decision-support-software/2479271/Bausch + Lomb announced that its affiliate has entered into an agreement with Lochan LLC to develop the next-generation of Bausch + Lomb’s eyeTELLIGENCE clinical decision support software. Using the existing cloud-based infrastructure of eyeTELLIGENCE, this analytical software is being designed t
- Myra Vision Closes $17M In Series A Financing to Advance Glaucoma Devicehttps://modernod.com/news/myra-vision-closes-17m-in-series-a-financing-to-advance-glaucoma-device/2479247/Myra Vision announced the closing of its $17 million Series A financing, which will be used to advance product development, scale infrastructure, and expand their team in order to support the development of the first of its kind glaucoma treatment device. The financi
- Neurophth Therapeutics and Hopstem Biotechnology Partner to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for Ocular Diseaseshttps://modernod.com/news/neurophth-therapeutics-and-hopstem-biotechnology-partner-to-develop-human-induced-pluripotent-stem-cell-derived-therapies-for-ocular-diseases/2479248/Neurophth Biotechnology and Hopstem Biotechnology announced a strategic partnership aiming to provide human iPSC-derived cell therapy for ocular diseases. The partnership leverages Neurophth’s experience in global gene/cell therapy drugs development and understanding of ophthalmic di
- Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicoxs-completes-pre-defined-enrollment-of-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479250/Nicox announced that more than 200 patients, the pre-defined target, have been randomized in the NCX 4251 Mississippi phase 2b blepharitis clinical trial. Topline results are expected to be announced during September 2021. “Blepharitis is a highly prevalent eye condition with frequent exac
- Samsara Vision: Patients Blinded by Macular Degeneration May Benefit From Implant Technologyhttps://modernod.com/news/samsara-vision-reports-that-patients-blinded-by-macular-degeneration-benefit-from-milestone-in-implant-technology/2479242/Samsara Vision announced the first successful clinical cases in Europe using their smaller-incision new-generation implantable miniature telescope (SING IMT) for people living with late-stage age-related macular degeneration (AMD). The SING IMT, performed with the TSert delivery system, was succe
- Vyluma Launches With Myopia Treatment In Phase 3 Developmenthttps://modernod.com/news/vyluma-inc-launches-with-robust-opthalmic-portfolio-leading-with-a-pharmaceutical-treatment-in-phase-iii-for-myopia/2479239/Vyluma announced its establishment as a wholly-owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions. The pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eye drop to slow the progression of myopia in children. NVK002 is currently in late phase 3